^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Bloodhound™ MPN panel

    Company:
    Precipio
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    1m
    Precipio expands Bloodhound™ MPN Panel by adding CALR mutation subtyping (Precipio Press Release)
    "Precipio, Inc...announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024—August 8, 2024)."
    Launch
    |
    Bloodhound™ MPN panel